Skip to main content

Trinity College Dublin, The University of Dublin

Menu Search


Trinity College Dublin By using this website you consent to the use of cookies in accordance with the Trinity cookie policy. For more information on cookies see our cookie policy.

      
Profile Photo

Dr. Kathy Gately

Clinical Senior Lecturer (Clinical Medicine)

 


Dr. Kathy Gately graduated with a BSc from University College Dublin and a PhD from the Department of Biochemistry, National University of Ireland Galway in 2000. During her PhD she spent six months at the University of California Los Angeles. She then worked as a postdoctoral fellow in the Dept. of Haematology with Prof. Mark Lawler and Prof. Shaun McCann where she carried out research on the novel targeted agent Imatinib in CML patients. In 2004, Dr. Gately was appointed as a Clinical Lecturer with Prof. Ken O'Byrne in the Dept. of Clinical Medicine. She was instrumental in the establishment of the Lung Cancer Biobank which supports research and clinical trials within the Translational Oncology Research Group (TORG). Dr. Gately has previously supervised 4 MD, 2 PhD and 12 MSc students. The main focus of Dr. Gately's research group is (i) the identification of novel prognostic/predictive biomarkers and therapeutic targets to improve treatment options for patients with cancer (ii) elucidating mechanisms of resistance to targeted therapies, in particular PI3K and EGFR inhibitors (iii) the role of the liquid biopsy in cancer diagnosis and treatment. Dr. Gately delivers lectures to undergraduate students in Molecular Medicine as well as the MSc in Molecular Medicine and Translational Oncology. She is editor of a recent book entitled: "Lung Cancer: A Comprehensive Review" Nova Publishers 2013. Dr. Gately is currently leading a research collaboration with Inflection Biosciences Ltd, an Irish company developing targeted small molecule treatments for cancer. The research examines the effectiveness of a panel of the company's targeted PIM kinase inhibitors in the treatment of thoracic malignancy. In particular, solid tumours that have become resistant to other forms of treatment. This research is supported in part by an Innovation Partnership Program award from Enterprise Ireland (EI).
  Bioinformatics   Biological Sciences   Biology   Biomedical sciences   Biostatistical methods   Breast cancer   Cancer genetics and cell biology including metastasis   Cardiothoracic surgery   Cell Death   Cellular Biology   Clinical genetics   Clinical research, trials   Cytogenetics   Diagnostic bioimaging   Gene targeting in breast cancer   Gene therapy   Gene transcription in human cancer   Genetic/Molecular epidemiology   Genetics   Haemotology   Human genetics   Imaging Techniques   Immunoassays   Instrumentation development   Medical technology   Medicine   Molecular Biology   Molecular Genetics   Monoclonal antibodies   Natural Sciences   Quantitative and molecular genetics   Regulatory methods of gene expression   RNA processing, stability and degradation   Stem Cell Biology   Stem Cell biology and hematopoiesis   Systematic Biology   Therapeutic and Clinical oncology   Tumour immunology and immunotherapy
Language Skill Reading Skill Writing Skill Speaking
English Fluent Fluent Fluent
French Basic Basic Basic
German Basic Basic Basic
Irish Medium Medium Medium
Details Date From Date To
AACR
ETOP
BTOG
ESBB
IASLC
ESMO
Irish Thoracic Society (ITS)
ERS
Gaule P, Mukherjee N, Corkery B, Eustace AJ, Gately K, Roche S, O'Connor R, O'Byrne KJ, Walsh N, Duffy MJ, Crown J, O'Donovan N., Dasatinib Treatment Increases Sensitivity to c-Met Inhibition in Triple-Negative Breast Cancer Cells., Cancers, 11, (4), 2019, Journal Article, PUBLISHED  DOI
Heavey S, Dowling P, Moore G, Barr MP, Kelly N, Maher SG, Cuffe S, Finn SP, O'Byrne KJ, Gately K., Development and characterisation of a panel of phosphatidylinositide 3-kinase - mammalian target of rapamycin inhibitor resistant lung cancer cell lines., Scientific Reports, 8, (1), 2018, p1652-, Journal Article, PUBLISHED  TARA - Full Text  DOI
Kerr KM, Dafni U, Schulze K, Thunnissen E, Bubendorf L, Hager H, Finn S, Biernat W, Vliegen L, Losa JH, Marchetti A, Cheney R, Warth A, Speel EJ, Blackhall F, Monkhorst K, Jantus Lewintre E, Tischler V, Clark C, Bertran-Alamillo J, Meldgaard P, Gately K, Wrona A, Vandenberghe P, Felip E, De Luca G, Savic S, Muley T, Smit EF, Dingemans AC, Priest L, Baas P, Camps C, Weder W, Polydoropoulou V, Geiger TR, Kammler R, Sumiyoshi T, Molina MA, Shames DS, Stahel RA, Peters S, ETOP Lungscape Consortium., Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscape Project., Annals of oncology : official journal of the European Society for Medical Oncology, 29, (1), 2018, p200-208 , Journal Article, PUBLISHED  DOI
Hutchinson RA, Coleman HG, Gately K, Young V, Nicholson S, Cummins R, Kay E, Hynes SO, Dunne PD, Senevirathne S, Hamilton PW, McArt DG, Longley DB, IHC-based subcellular quantification provides new insights into prognostic relevance of FLIP and procaspase-8 in non-small-cell lung cancer, Cell Death Discovery, 14, (3), 2017, p17050-, Journal Article, PUBLISHED
Adams, M.N. and Burgess, J.T. and He, Y. and Gately, K. and Snell, C. and Zhang, S.-D. and Hooper, J.D. and Richard, D.J. and O'Byrne, K.J., Expression of CDCA3 Is a Prognostic Biomarker and Potential Therapeutic Target in Nonâ€"Small Cell Lung Cancer, Journal of Thoracic Oncology, 12, (7), 2017, p1071-1084 , Notes: [cited By 0], Journal Article, PUBLISHED  DOI
Collins, D.M. and Gately, K. and Hughes, C. and Edwards, C. and Davies, A. and Madden, S.F. and O'Byrne, K.J. and O'Donovan, N. and Crown, J., Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines, Cellular Immunology, 319, 2017, p35-42 , Notes: [cited By 0], Journal Article, PUBLISHED  DOI
Burgess J.T, Bolderson E, Adams M.N, Baird A.-M, Zhang S.-D, Gately K.A, Umezawa K, O'Byrne K.J, Richard D.J, Activation and cleavage of SASH1 by caspase-3 mediates an apoptotic response, Cell Death and Disease, 7, (11), 2016, pe2469-, Notes: [Export Date: 3 April 2017], Journal Article, PUBLISHED  TARA - Full Text  DOI  URL
Heavey S, Cuffe S, Finn S, Young V, Ryan R, Nicholson S, Leonard N, McVeigh N, Barr M, O'Byrne K, Gately K, In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC, Oncotarget, 7, (48), 2016, p79526 - 79543, Notes: [Export Date: 3 April 2017], Journal Article, PUBLISHED  TARA - Full Text  DOI  URL
Cathcart M.-C, Useckaite Z, Drakeford C, Semik V, Lysaght J, Gately K, O'Byrne K.J, Pidgeon G.P, Anti-cancer effects of baicalein in non-small cell lung cancer in-vitro and in-vivo, BMC Cancer, 16, (1), 2016, p707-, Notes: [Cited By :2 Export Date: 3 April 2017], Journal Article, PUBLISHED  TARA - Full Text  DOI  URL
Hallinan N, Finn S, Cuffe S, Rafee S, O'Byrne K, Gately K, Targeting the fibroblast growth factor receptor family in cancer, Cancer Treatment Reviews, 46, 2016, p51 - 62, Notes: [Cited By :6 Export Date: 3 April 2017], Journal Article, PUBLISHED  DOI  URL
  

Page 1 of 5
Gaule P, Dasatinib, Cancers, 2019, Journal Article, PUBLISHED
Gately K, Advancing the treatment of non-small cell lung cancer - a combination approach, Cancer Professional, 2018, Journal Article, PUBLISHED
Kathy Gately, Lung Cancer : A Comprehensive Overview, First, New York U.S., Nova Science Publishers Inc, 2013, Book, PUBLISHED